Analysis Group, Inc.
11
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
9.1%
1 terminated/withdrawn out of 11 trials
87.5%
+1.0% vs industry average
9%
1 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Epithelioid Sarcoma Natural History Study
Role: collaborator
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
Role: collaborator
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Role: collaborator
A Trial of Same-Day Testing and Treatment to Improve Outcomes Among Symptomatic Patients Newly Diagnosed With HIV
Role: collaborator
Understanding Patient Experience and Preferences for the QT Scanner Compared to Mammography
Role: collaborator
Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
Role: collaborator
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Role: collaborator
Immediate Fast-Track Versus Standard Care for Persons Living With HIV in Haiti
Role: collaborator
Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults
Role: collaborator
Same-Day Treatment With Genvoya vs. EFV/TDF/3TC
Role: collaborator
Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotarix Vaccination
Role: collaborator
All 11 trials loaded